The difference in immunogenic responses to COVID-19 vaccines in cancer patients receiving chemotherapy versus non-chemotherapy treatment
- Conditions
- Cancer patients who immunized with two doses of ChAdOx1 nCoV-19 (viral vector) or CoronaVac (inactivated virus) COVID-19 vaccinesImmunogenicity, seroconversion rate, COVID-19 vaccine, cancer patients
- Registration Number
- TCTR20221001004
- Lead Sponsor
- Chulabhorn Royal Academy
- Brief Summary
The chemotherapy group had significantly lower median anti-SARS-CoV-2 S IgG titers compared with those in the non-chemotherapy group (26 vs 237 U/ml, p less than 0.001) - The anti-SARS-CoV-2 S antibody seroconversion rate after vaccination in the chemotherapy group was significantly lower than that in the non-chemotherapy group (78.9% vs 96.5% , p 0.001) - There was no difference in the reported local or systemic adverse events between the chemotherapy and non-chemotherapy groups
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 185
Patients were eligible if they were Thai citizens aged 18 years or older with histologically or cytologically confirmed solid malignancy, in either early or advanced stages. Other inclusion criteria were an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 3 and currently receiving systemic anticancer therapy or active surveillance/follow-up within five years after completed cancer treatment.
Hematologic malignancy, Concurrent chemoradiotherapy, absolute neutrophil count of less than 1500 cells per mcl or platelet count of less than 100,000 per mcl, expected life expectancy of less than 3 months, HIV infection, pregnancy, and breastfeeding.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The immunogenicity of COVID-19 vaccine 6 months Anibody level
- Secondary Outcome Measures
Name Time Method the anti-SARS-CoV-2 S antibody seroconversion rate 6 months A proportion,Safety 7 days A proportion,the effects of the COVID-19 vaccine type on the anti-SARS-CoV-2 S antibody titer 6 months Antibody level,the effects of the COVID-19 vaccine type on the seroconversion rate 6 months A proportion